[go: up one dir, main page]

ATE227992T1 - Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens - Google Patents

Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens

Info

Publication number
ATE227992T1
ATE227992T1 AT91917276T AT91917276T ATE227992T1 AT E227992 T1 ATE227992 T1 AT E227992T1 AT 91917276 T AT91917276 T AT 91917276T AT 91917276 T AT91917276 T AT 91917276T AT E227992 T1 ATE227992 T1 AT E227992T1
Authority
AT
Austria
Prior art keywords
androstene
delta
weight loss
beta
promoting
Prior art date
Application number
AT91917276T
Other languages
English (en)
Inventor
Henry A Lardy
Bruce E Partridge
Original Assignee
Humanetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanetics Corp filed Critical Humanetics Corp
Application granted granted Critical
Publication of ATE227992T1 publication Critical patent/ATE227992T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Disintegrating Or Milling (AREA)
AT91917276T 1990-08-29 1991-08-28 Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens ATE227992T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57515690A 1990-08-29 1990-08-29
PCT/US1991/006147 WO1992003925A1 (en) 1990-08-29 1991-08-28 Treatment process for promoting weight loss employing a substituted δ5-androstene
US43981603P 2003-01-13 2003-01-13

Publications (1)

Publication Number Publication Date
ATE227992T1 true ATE227992T1 (de) 2002-12-15

Family

ID=37772553

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917276T ATE227992T1 (de) 1990-08-29 1991-08-28 Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens

Country Status (10)

Country Link
US (1) US5296481A (de)
EP (1) EP0547151B1 (de)
JP (1) JP2973031B2 (de)
AT (1) ATE227992T1 (de)
AU (1) AU647528B2 (de)
CA (1) CA2090759A1 (de)
DE (1) DE69133158T2 (de)
DK (1) DK0547151T3 (de)
ES (1) ES2184729T3 (de)
WO (2) WO1992003925A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
WO1992003925A1 (en) * 1990-08-29 1992-03-19 Humanetics Corporation Treatment process for promoting weight loss employing a substituted δ5-androstene
US5807848A (en) * 1990-08-29 1998-09-15 Humanetics Corporation Use of dehydroepeiandrosterone-3-carboxylates to control body weight
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
CA2148373A1 (en) * 1993-09-02 1995-03-09 Henry A. Lardy Delta 5-androstenes useful for promoting weight maintenance or weight loss and treatment process
WO1995010527A1 (en) * 1993-10-13 1995-04-20 Neurocrine Biosciences, Inc. 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
WO1997037664A2 (en) 1996-04-09 1997-10-16 British Technology Group Ltd. Use of 7 alpha-substituted steroids to treat neuropsychiatric, immune or endocrine disorders
US6686486B1 (en) 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
US5869709A (en) * 1997-05-07 1999-02-09 Humanetics Corporation Process for effecting allylic oxidation
US6252119B1 (en) * 1997-07-28 2001-06-26 Salvador Jorge Antonio Riberiro Copper-catalysed allylic oxidation using alkyl hydroperoxide
AU8779898A (en) * 1997-08-11 1999-03-01 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US6372732B1 (en) * 1997-11-19 2002-04-16 Humanetics Corporation Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus
WO1999047485A1 (en) 1998-03-18 1999-09-23 Humanetics Corporation Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US6153606A (en) 1998-10-16 2000-11-28 Humanetics Corporation Memory enhancement by the administration of Δ5-androstene-3β-ol-7,17-dione and 3β esters thereof
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
FR2793491B1 (fr) * 1999-05-10 2005-01-21 Mayoly Spindler Lab Procede de synthese stereospecifique par oxydation allylique de composes allyliques
DE60045751D1 (de) * 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden
WO2002043737A1 (en) * 2000-11-30 2002-06-06 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
FR2818135B1 (fr) 2000-12-15 2003-02-14 Oreal Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide
FR2818148B1 (fr) 2000-12-15 2005-06-24 Oreal Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
FR2820745A1 (fr) * 2001-02-14 2002-08-16 Oreal Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone
US6399085B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method of moisturizing the skin by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6399084B1 (en) 2001-03-05 2002-06-04 Humanetics Corporation Method for diminishing wrinkles and fine lines of the skin by the topical application of Δ5-androstene-3β-ol-7, 17 dione and metabolizable precursors thereof
US6465446B1 (en) 2001-03-12 2002-10-15 John C. Dykstra Treatment of dermatitis by the topical application of Δ5-androstene-3β-ol-7,17 dione and metabolizable precursors thereof
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
US6746182B2 (en) * 2001-07-27 2004-06-08 Abb Vetco Gray Inc. Keel joint arrangements for floating platforms
FR2830015A1 (fr) * 2001-09-27 2003-03-28 Berkem Sa Compositions a base de derives de steroides
US20060217357A1 (en) * 2003-01-13 2006-09-28 Humanetics Corporation Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal
US20060135499A1 (en) * 2003-01-13 2006-06-22 Zenk John L Method of achieving accelerated weight loss by administration of a weight loss accelerating agent to a dieting mammal
US7199116B2 (en) * 2003-01-13 2007-04-03 Humanetics Corporation Method of modulating the basal metabolic rate of a dieting mammal by administration of a metabolic modulating agent to the dieting mammal
US20040242618A1 (en) * 2003-04-01 2004-12-02 Lardy Henry A. Antiandrogens with marginal agonist activity and methods of use
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20080153792A1 (en) * 2006-11-17 2008-06-26 Frincke James M Drug Identification and Treatment Method
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8354396B2 (en) * 2006-11-17 2013-01-15 Harbor Therapeutics, Inc. Drug identification and treatment method
JP2011527986A (ja) * 2008-04-03 2011-11-10 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬の固体状態形態
US20100227841A1 (en) * 2008-09-24 2010-09-09 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
US20110129423A1 (en) * 2009-11-30 2011-06-02 Frincke James M Anticancer compounds and screening method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
US4511511A (en) * 1982-12-15 1985-04-16 Crozer-Chester Medical Center Prednisolone derivatives
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
IL72566A (en) * 1983-08-02 1988-08-31 Research Corp Androst-5-en-17-one and 5alpha-androstan-17-one derivatives and pharmaceutical compositions containing the same
DE3418491A1 (de) * 1984-05-18 1985-11-21 Merck Patent Gmbh, 6100 Darmstadt Diaminosaeurederivate
AU601184B2 (en) * 1986-05-21 1990-09-06 Research Corporation Steroids useful as anti-cancer and anti-obesity agents
US4897390A (en) * 1987-07-21 1990-01-30 Ruhe Rodney C Novel anti-obesity compounds and method of use
US4898694A (en) * 1987-11-25 1990-02-06 Schwartz Arthur G 17-Hydroxy-steroids
WO1992003925A1 (en) * 1990-08-29 1992-03-19 Humanetics Corporation Treatment process for promoting weight loss employing a substituted δ5-androstene

Also Published As

Publication number Publication date
AU8541891A (en) 1992-03-30
AU647528B2 (en) 1994-03-24
WO2004062606A3 (en) 2004-11-25
CA2090759A1 (en) 1992-03-01
DE69133158D1 (de) 2003-01-02
EP0547151A1 (de) 1993-06-23
JPH06508345A (ja) 1994-09-22
WO1992003925A1 (en) 1992-03-19
JP2973031B2 (ja) 1999-11-08
US5296481A (en) 1994-03-22
ES2184729T3 (es) 2003-04-16
DE69133158T2 (de) 2003-07-17
DK0547151T3 (da) 2003-03-17
EP0547151B1 (de) 2002-11-20
EP0547151A4 (en) 1993-10-13
WO2004062606A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE227992T1 (de) Behandlungsverfahren zur förderung des gewichtsverlustes unter verwendung eines substituierten delta-5-androstens
DE69329856D1 (de) Ester derivate von 4-aza-steroiden
NO985575L (no) FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese
NO20063667L (no) Anvendelse av et anti-mikrotubulimiddel for fremstilling av en farmasoytisk blanding for behandling eller forhindring av kirurgiske adhesjoner
AU2559897A (en) Androgen derivatives for use in the inhibition of sex steroid activity
NO954611D0 (no) Metoder og preparater for anvendelse i behandling av benigne gynekologiske sykdommer
NO940638L (de)
EP0367576A3 (de) Östrogenkernderivate und deren Gebrauch als Inhibitoren von sexuellen Steroiden
NO159278C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 1-alkyl-androsta-1,4-dien-3,17-dioner.
DE69018799D1 (de) IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie.
DE69634472D1 (de) Adrenal-Cortikosteroide enthaltende therapeutische Zusammensetzung zur äusserlichen Anwendung für Dermatitis-Behandlung
AU7679494A (en) Delta5-androstenes useful for promoting weight maintenance or weight loss and treatment process
DE69010025D1 (de) Verfahren zur Herstellung von 14-Alpha-hydroxy-4-androsten-3,6,17, trion.
DE69115745D1 (de) Verwendung von Steroidderivaten zur Behandlung der Endometriose
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DE68922688D1 (de) Kombinierung von tobramycin und steroiden für topische ophthalmische verwendung.
EP0559706A4 (de)
PT80008A (en) A process for the preparations of a 2alpha-cyano-4alpha,alpha5--epoxyandrostan-3,17-dione
MX9700227A (es) Metodo para preparar ganado vacuno para ser sacrificado.
ATE128188T1 (de) Menschliches gamma-interferon, verfahren zu seiner herstellung und seine verwendung.
JPS6470061A (en) Deodorant for livestock and its preparation
YU60496A (sh) Novi 16,17-seko-,16-keto-i 16-oksimino-17- supstituisani steroidi estratrienske i androstenske serije sa biološkom aktivnošću
Naito et al. Light-and-dark signal for the initiation of prolactin surges in cervically stimulated rats
NZ510253A (en) Neuroprotection
FR2421911A2 (fr) Nouveaux derives du pregn 4-ene, leur procede de preparation et leur application comme medicament

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0547151

Country of ref document: EP

REN Ceased due to non-payment of the annual fee